The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VUMERITY (Biogen Australia Pty Ltd)
Product name
VUMERITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
diroximel fumarate
Registration type
NCE/NBE
Indication
VUMERITY (enteric capsule) is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.